Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States-2019-2020.
antigenic drift
influenza
test-negative
vaccination
vaccine effectiveness
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
06 12 2021
06 12 2021
Historique:
received:
16
09
2020
pubmed:
29
12
2020
medline:
15
3
2022
entrez:
28
12
2020
Statut:
ppublish
Résumé
At the start of the 2019-2020 influenza season, concern arose that circulating B/Victoria viruses of the globally emerging clade V1A.3 were antigenically drifted from the strain included in the vaccine. Intense B/Victoria activity was followed by circulation of genetically diverse A(H1N1)pdm09 viruses that were also antigenically drifted. We measured vaccine effectiveness (VE) in the United States against illness from these emerging viruses. We enrolled outpatients aged ≥6 months with acute respiratory illness at 5 sites. Respiratory specimens were tested for influenza by reverse-transcriptase polymerase chain reaction (RT-PCR). Using the test-negative design, we determined influenza VE by virus subtype/lineage and genetic subclades by comparing odds of vaccination in influenza cases versus test-negative controls. Among 8845 enrollees, 2722 (31%) tested positive for influenza, including 1209 (44%) for B/Victoria and 1405 (51%) for A(H1N1)pdm09. Effectiveness against any influenza illness was 39% (95% confidence interval [CI]: 32-44), 45% (95% CI: 37-52) against B/Victoria and 30% (95% CI: 21-39) against A(H1N1)pdm09-associated illness. Vaccination offered no protection against A(H1N1)pdm09 viruses with antigenically drifted clade 6B.1A 183P-5A+156K HA genes (VE 7%; 95% CI: -14 to 23%) which predominated after January. Vaccination provided protection against influenza illness, mainly due to infections from B/Victoria viruses. Vaccine protection against illness from A(H1N1)pdm09 was lower than historically observed effectiveness of 40%-60%, due to late-season vaccine mismatch following emergence of antigenically drifted viruses. The effect of drift on vaccine protection is not easy to predict and, even in drifted years, significant protection can be observed.
Sections du résumé
BACKGROUND
At the start of the 2019-2020 influenza season, concern arose that circulating B/Victoria viruses of the globally emerging clade V1A.3 were antigenically drifted from the strain included in the vaccine. Intense B/Victoria activity was followed by circulation of genetically diverse A(H1N1)pdm09 viruses that were also antigenically drifted. We measured vaccine effectiveness (VE) in the United States against illness from these emerging viruses.
METHODS
We enrolled outpatients aged ≥6 months with acute respiratory illness at 5 sites. Respiratory specimens were tested for influenza by reverse-transcriptase polymerase chain reaction (RT-PCR). Using the test-negative design, we determined influenza VE by virus subtype/lineage and genetic subclades by comparing odds of vaccination in influenza cases versus test-negative controls.
RESULTS
Among 8845 enrollees, 2722 (31%) tested positive for influenza, including 1209 (44%) for B/Victoria and 1405 (51%) for A(H1N1)pdm09. Effectiveness against any influenza illness was 39% (95% confidence interval [CI]: 32-44), 45% (95% CI: 37-52) against B/Victoria and 30% (95% CI: 21-39) against A(H1N1)pdm09-associated illness. Vaccination offered no protection against A(H1N1)pdm09 viruses with antigenically drifted clade 6B.1A 183P-5A+156K HA genes (VE 7%; 95% CI: -14 to 23%) which predominated after January.
CONCLUSIONS
Vaccination provided protection against influenza illness, mainly due to infections from B/Victoria viruses. Vaccine protection against illness from A(H1N1)pdm09 was lower than historically observed effectiveness of 40%-60%, due to late-season vaccine mismatch following emergence of antigenically drifted viruses. The effect of drift on vaccine protection is not easy to predict and, even in drifted years, significant protection can be observed.
Identifiants
pubmed: 33367650
pii: 6048924
doi: 10.1093/cid/ciaa1884
pmc: PMC8664438
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e4244-e4250Subventions
Organisme : NIH HHS
ID : UL1TR001857
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001034
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001857
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001039
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001035
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001038
Pays : United States
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Références
Lancet Infect Dis. 2016 Aug;16(8):942-51
pubmed: 27061888
MMWR Morb Mortal Wkly Rep. 2019 Oct 11;68(40):880-884
pubmed: 31600182
Clin Infect Dis. 2021 Aug 2;73(3):386-392
pubmed: 32270198
N Engl J Med. 2020 Jul 23;383(4):309-320
pubmed: 32640124
MMWR Recomm Rep. 2019 Aug 23;68(3):1-21
pubmed: 31441906
Clin Infect Dis. 2021 Apr 8;72(7):1147-1157
pubmed: 32006430
Vaccine. 2013 Jun 26;31(30):3104-9
pubmed: 23624093
Clin Infect Dis. 2019 May 17;68(11):1798-1806
pubmed: 30204854
Vaccine. 2009 Nov 5;27(47):6546-9
pubmed: 19729083
MMWR Morb Mortal Wkly Rep. 2020 Jan 17;69(2):40-43
pubmed: 31945035
J Infect Dis. 2020 Jan 1;221(1):8-15
pubmed: 31665373
Clin Infect Dis. 2016 Dec 15;63(12):1564-1573
pubmed: 27702768
MMWR Recomm Rep. 2009 Jul 31;58(RR-8):1-52
pubmed: 19644442
N Engl J Med. 2017 Aug 10;377(6):534-543
pubmed: 28792867
MMWR Morb Mortal Wkly Rep. 2020 Feb 21;69(7):177-182
pubmed: 32078591
Clin Infect Dis. 2016 Dec 29;64(5):544-550
pubmed: 28039340